Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q2 2026

Sonoma Pharmaceuticals Q2 2026 Results: Net Loss of $66K, Loss Narrows

Sonoma Pharmaceuticals reported a significant revenue increase to $13.58 million for the six months ended September 30, 2026, compared to $9.62 million in the prior year. The company successfully narrowed its net loss to $396,000 from $1.78 million, driven by improved gross profits and a return to positive income from operations in the most recent quarter.

Q2 2026 at a glance · $ million
MetricQ2 2026Q2 2025
Revenue7.25.6
Gross profit2.82.1
Profit before tax0.4-0.7
Net income-0.1-0.5
EPS (diluted, $ a share)$-0.01$-0.32

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+28.0%
Gross margin39.1%
Operating margin4.0%
Source

10-Q filed with the SEC, NASDAQ: SNOA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Sonoma Pharmaceuticals, Inc.: key numbers

Share price
$0.8802Close, Nov 16
Market cap
$4.46M
Shares outstanding
5.06MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Sonoma Pharmaceuticals, Inc.

All →
4:30 PM ET 8-K
Other 8-K Filing

Sonoma Pharmaceuticals Other 8-K Filing

Sonoma Pharmaceuticals adopted a Section 382 Rights Agreement (poison pill) to protect its net operating loss carryforwards (NOLs) from being limited by an 'ownership change'. The agreement issues one preferred stock purchase right for each share of common stock, intended to deter any person or group from acquiring 5% or more of the company's shares.

Counterparty
Computershare Inc.
6:01 AM ET 8-K
Shareholder Meeting

Sonoma Pharmaceuticals Shareholder Meeting

Sonoma Pharmaceuticals held its annual meeting of stockholders on September 16, 2026, where shareholders elected Jerry McLaughlin as a Class III director. Stockholders also approved executive compensation on an advisory basis and ratified the appointment of Frazier & Deeter, LLC as the company's independent accounting firm for the fiscal year ending March 31, 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.